APO Research
Talk to an analyst

APO RESEARCH · REPORT

Drugs for Osteoarthritis Pain

Drugs for Osteoarthritis Pain market, the main role of osteoarthritis pain drugs is to relieve pain, and cannot slow the progress of osteoarthritis.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Drugs for Osteoarthritis Pain market, the main role of osteoarthritis pain drugs is to relieve pain, and cannot slow the progress of osteoarthritis.

Selected research

Market Outlook & Growth Opportunities

Global Drugs for Osteoarthritis Pain Market Outlook and Growth Opportunities 2026

22 December 2025208 pages

Choose your research edition.

Industry ResearchDrugs for Osteoarthritis Pain Industry Research Report 2026132 pages · $2,950 USDIndustry Growth & TrendsGlobal Drugs for Osteoarthritis Pain Industry Growth and Trends Forecast to 2032111 pages · $3,450 USDMarket StructureGlobal Drugs for Osteoarthritis Pain Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Drugs for Osteoarthritis Pain Market Outlook and Growth Opportunities 2026208 pages · $4,250 USDMarket Analysis & ForecastGlobal Drugs for Osteoarthritis Pain Market Analysis and Forecast 2026-2032201 pages · $4,950 USD

Market perspective

Drugs for Osteoarthritis Pain market, the main role of osteoarthritis pain drugs is to relieve pain, and cannot slow the progress of osteoarthritis.

North America is the largest Drugs for Osteoarthritis Pain market with about 36% market share. Europe is follower, accounting for about 27% market share.

The key players are Pfizer, Johnson & Johnson, GlaxoSmithKline, Bayer, Eli Lilly, Novartis, Sanofi, Horizon Pharma, Abbott, Mylan, Daiichi Sankyo, TEVA, Almatica Pharma, Astellas Pharma, Tide Pharmaceutical, Iroko Pharmaceuticals, Hengrui Pharmaceutical, Abiogen Pharma etc. Top 5 companies occupied about 66% market share.

Read the full market overview

This report provides an overview of the global Drugs for Osteoarthritis Pain market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Drugs for Osteoarthritis Pain and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Drugs for Osteoarthritis Pain revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Drugs for Osteoarthritis Pain market.

Drugs for Osteoarthritis Pain Segment by Company

Pfizer

Johnson & Johnson

GlaxoSmithKline

Bayer

Eli Lilly

Novartis

Sanofi

Horizon Pharma

Abbott

Mylan

Daiichi Sankyo

TEVA

Almatica Pharma

Astellas Pharma

Tide Pharmaceutical

Iroko Pharmaceuticals

Hengrui Pharmaceutical

Abiogen Pharma

Drugs for Osteoarthritis Pain Segment by Type

Oral

Injection

External

Drugs for Osteoarthritis Pain Segment by Application

Medical Care

Personal Care

Drugs for Osteoarthritis Pain Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Drugs for Osteoarthritis Pain status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Drugs for Osteoarthritis Pain key companies, revenue, market share, and recent developments.

3. To split the Drugs for Osteoarthritis Pain breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Drugs for Osteoarthritis Pain market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Drugs for Osteoarthritis Pain significant trends, drivers, influence factors in global and regions.

6. To analyze Drugs for Osteoarthritis Pain competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Drugs for Osteoarthritis Pain market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Drugs for Osteoarthritis Pain and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Drugs for Osteoarthritis Pain.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Drugs for Osteoarthritis Pain industry.

Chapter 3: Detailed analysis of Drugs for Osteoarthritis Pain company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Drugs for Osteoarthritis Pain in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Drugs for Osteoarthritis Pain in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Drugs for Osteoarthritis Pain Industry Trends Table 2. Drugs for Osteoarthritis Pain Industry Drivers Table 3. Drugs for Osteoarthritis Pain Industry Opportunities and Challenges Table 4. Drugs for Osteoarthritis Pain Industry Restraints Table 5. Global Drugs for Osteoarthritis Pain Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Drugs for Osteoarthritis Pain Revenue Share by Company (2021-2026) Table 7. Global Drugs for Osteoarthritis Pain Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Drugs for Osteoarthritis Pain Key Company Manufacturing Base & Headquarters Table 9. Global Drugs for Osteoarthritis Pain Company, Product Type & Application Table 10. Global Drugs for Osteoarthritis Pain Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Drugs for Osteoarthritis Pain by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Oral Table 15. Significant Companies of Injection Table 16. Significant Companies of External Table 17. Global Drugs for Osteoarthritis Pain Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 18. Global Drugs for Osteoarthritis Pain Sales Value by Type (2021-2026) & (US$ Million) Table 19. Global Drugs for Osteoarthritis Pain Sales Value by Type (2027-2032) & (US$ Million) Table 20. Global Drugs for Osteoarthritis Pain Sales Value Share by Type (2021-2026) Table 21. Global Drugs for Osteoarthritis Pain Sales Value Share by Type (2027-2032) Table 22. Significant Companies of Medical Care Table 23. Significant Companies of Personal Care Table 24. Global Drugs for Osteoarthritis Pain Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Drugs for Osteoarthritis Pain Sales Value by Application (2021-2026) & (US$ Million) Table 26. Global Drugs for Osteoarthritis Pain Sales Value by Application (2027-2032) & (US$ Million) Table 27. Global Drugs for Osteoarthritis Pain Sales Value Share by Application (2021-2026) Table 28. Global Drugs for Osteoarthritis Pain Sales Value Share by Application (2027-2032) Table 29. Global Drugs for Osteoarthritis Pain Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Drugs for Osteoarthritis Pain Sales Value by Region (2021-2026) & (US$ Million) Table 31. Global Drugs for Osteoarthritis Pain Sales Value Share by Region (2021-2026) Table 32. Global Drugs for Osteoarthritis Pain Sales Value by Region (2027-2032) & (US$ Million) Table 33. Global Drugs for Osteoarthritis Pain Sales Value Share by Region (2027-2032) Table 34. Global Drugs for Osteoarthritis Pain Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Drugs for Osteoarthritis Pain Sales Value by Country (2021-2026) & (US$ Million) Table 36. Global Drugs for Osteoarthritis Pain Sales Value Market Share by Country (2021-2026) Table 37. Global Drugs for Osteoarthritis Pain Sales Value by Country (2027-2032) & (US$ Million) Table 38. Global Drugs for Osteoarthritis Pain Sales Value Market Share by Country (2027-2032) Table 39. Pfizer Company Information Table 40. Pfizer Business Overview Table 41. Pfizer Drugs for Osteoarthritis Pain Revenue (US$ Million) and Gross Margin (2021-2026) Table 42. Pfizer Drugs for Osteoarthritis Pain Product Portfolio Table 43. Pfizer Recent Development Table 44. Johnson & Johnson Company Information Table 45. Johnson & Johnson Business Overview Table 46. Johnson & Johnson Drugs for Osteoarthritis Pain Revenue (US$ Million) and Gross Margin (2021-2026) Table 47. Johnson & Johnson Drugs for Osteoarthritis Pain Product Portfolio Table 48. Johnson & Johnson Recent Development Table 49. GlaxoSmithKline Company Information Table 50. GlaxoSmithKline Business Overview Table 51. GlaxoSmithKline Drugs for Osteoarthritis Pain Revenue (US$ Million) and Gross Margin (2021-2026) Table 52. GlaxoSmithKline Drugs for Osteoarthritis Pain Product Portfolio Table 53. GlaxoSmithKline Recent Development Table 54. Bayer Company Information Table 55. Bayer Business Overview Table 56. Bayer Drugs for Osteoarthritis Pain Revenue (US$ Million) and Gross Margin (2021-2026) Table 57. Bayer Drugs for Osteoarthritis Pain Product Portfolio Table 58. Bayer Recent Development Table 59. Eli Lilly Company Information Table 60. Eli Lilly Business Overview Table 61. Eli Lilly Drugs for Osteoarthritis Pain Revenue (US$ Million) and Gross Margin (2021-2026) Table 62. Eli Lilly Drugs for Osteoarthritis Pain Product Portfolio Table 63. Eli Lilly Recent Development Table 64. Novartis Company Information Table 65. Novartis Business Overview Table 66. Novartis Drugs for Osteoarthritis Pain Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Novartis Drugs for Osteoarthritis Pain Product Portfolio Table 68. Novartis Recent Development Table 69. Sanofi Company Information Table 70. Sanofi Business Overview Table 71. Sanofi Drugs for Osteoarthritis Pain Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Sanofi Drugs for Osteoarthritis Pain Product Portfolio Table 73. Sanofi Recent Development Table 74. Horizon Pharma Company Information Table 75. Horizon Pharma Business Overview Table 76. Horizon Pharma Drugs for Osteoarthritis Pain Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Horizon Pharma Drugs for Osteoarthritis Pain Product Portfolio Table 78. Horizon Pharma Recent Development Table 79. Abbott Company Information Table 80. Abbott Business Overview Table 81. Abbott Drugs for Osteoarthritis Pain Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Abbott Drugs for Osteoarthritis Pain Product Portfolio Table 83. Abbott Recent Development Table 84. Mylan Company Information Table 85. Mylan Business Overview Table 86. Mylan Drugs for Osteoarthritis Pain Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. Mylan Drugs for Osteoarthritis Pain Product Portfolio Table 88. Mylan Recent Development Table 89. Daiichi Sankyo Company Information Table 90. Daiichi Sankyo Business Overview Table 91. Daiichi Sankyo Drugs for Osteoarthritis Pain Sales (), Value (US$ Million), Price () and Gross Margin (2021-2026) Table 92. Daiichi Sankyo Drugs for Osteoarthritis Pain Product Portfolio Table 93. Daiichi Sankyo Recent Development Table 94. TEVA Company Information Table 95. TEVA Business Overview Table 96. TEVA Drugs for Osteoarthritis Pain Sales (), Value (US$ Million), Price () and Gross Margin (2021-2026) Table 97. TEVA Drugs for Osteoarthritis Pain Product Portfolio Table 98. TEVA Recent Development Table 99. Almatica Pharma Company Information Table 100. Almatica Pharma Business Overview Table 101. Almatica Pharma Drugs for Osteoarthritis Pain Sales (), Value (US$ Million), Price () and Gross Margin (2021-2026) Table 102. Almatica Pharma Drugs for Osteoarthritis Pain Product Portfolio Table 103. Almatica Pharma Recent Development Table 104. Astellas Pharma Company Information Table 105. Astellas Pharma Business Overview Table 106. Astellas Pharma Drugs for Osteoarthritis Pain Sales (), Value (US$ Million), Price () and Gross Margin (2021-2026) Table 107. Astellas Pharma Drugs for Osteoarthritis Pain Product Portfolio Table 108. Astellas Pharma Recent Development Table 109. Tide Pharmaceutical Company Information Table 110. Tide Pharmaceutical Business Overview Table 111. Tide Pharmaceutical Drugs for Osteoarthritis Pain Sales (), Value (US$ Million), Price () and Gross Margin (2021-2026) Table 112. Tide Pharmaceutical Drugs for Osteoarthritis Pain Product Portfolio Table 113. Tide Pharmaceutical Recent Development Table 114. Iroko Pharmaceuticals Company Information Table 115. Iroko Pharmaceuticals Business Overview Table 116. Iroko Pharmaceuticals Drugs for Osteoarthritis Pain Sales (), Value (US$ Million), Price () and Gross Margin (2021-2026) Table 117. Iroko Pharmaceuticals Drugs for Osteoarthritis Pain Product Portfolio Table 118. Iroko Pharmaceuticals Recent Development Table 119. Hengrui Pharmaceutical Company Information Table 120. Hengrui Pharmaceutical Business Overview Table 121. Hengrui Pharmaceutical Drugs for Osteoarthritis Pain Sales (), Value (US$ Million), Price () and Gross Margin (2021-2026) Table 122. Hengrui Pharmaceutical Drugs for Osteoarthritis Pain Product Portfolio Table 123. Hengrui Pharmaceutical Recent Development Table 124. Abiogen Pharma Company Information Table 125. Abiogen Pharma Business Overview Table 126. Abiogen Pharma Drugs for Osteoarthritis Pain Sales (), Value (US$ Million), Price () and Gross Margin (2021-2026) Table 127. Abiogen Pharma Drugs for Osteoarthritis Pain Product Portfolio Table 128. Abiogen Pharma Recent Development Table 129. Research Programs/Design for This Report Table 130. Authors List of This Report Table 131. Secondary Sources Table 132. Primary Sources List of Figures Figure 1. Drugs for Osteoarthritis Pain Product Image Figure 2. Global Drugs for Osteoarthritis Pain Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Drugs for Osteoarthritis Pain Market Size (2021-2032) & (US$ Million) Figure 4. Global Drugs for Osteoarthritis Pain Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Oral Image Figure 8. Injection Image Figure 9. External Image Figure 10. Global Drugs for Osteoarthritis Pain Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 11. Global Drugs for Osteoarthritis Pain Sales Value Share 2021 VS 2025 VS 2032 Figure 12. Global Drugs for Osteoarthritis Pain Sales Value Share by Type (2021-2032) Figure 13. Medical Care Image Figure 14. Personal Care Image Figure 15. Global Drugs for Osteoarthritis Pain Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Drugs for Osteoarthritis Pain Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Drugs for Osteoarthritis Pain Sales Value Share by Application (2021-2032) Figure 18. Global Drugs for Osteoarthritis Pain Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 19. Global Drugs for Osteoarthritis Pain Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 20. North America Drugs for Osteoarthritis Pain Sales Value (2021-2032) & (US$ Million) Figure 21. North America Drugs for Osteoarthritis Pain Sales Value Share by Country (%), 2025 VS 2032 Figure 22. Europe Drugs for Osteoarthritis Pain Sales Value (2021-2032) & (US$ Million) Figure 23. Europe Drugs for Osteoarthritis Pain Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Asia-Pacific Drugs for Osteoarthritis Pain Sales Value (2021-2032) & (US$ Million) Figure 25. Asia-Pacific Drugs for Osteoarthritis Pain Sales Value Share by Country (%), 2025 VS 2032 Figure 26. South America Drugs for Osteoarthritis Pain Sales Value (2021-2032) & (US$ Million) Figure 27. South America Drugs for Osteoarthritis Pain Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Middle East & Africa Drugs for Osteoarthritis Pain Sales Value (2021-2032) & (US$ Million) Figure 29. Middle East & Africa Drugs for Osteoarthritis Pain Sales Value Share by Country (%), 2025 VS 2032 Figure 30. USA Drugs for Osteoarthritis Pain Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 31. USA Drugs for Osteoarthritis Pain Sales Value Share by Type, 2025 VS 2032 & (%) Figure 32. USA Drugs for Osteoarthritis Pain Sales Value Share by Application, 2025 VS 2032 & (%) Figure 33. Canada Drugs for Osteoarthritis Pain Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. Canada Drugs for Osteoarthritis Pain Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. Canada Drugs for Osteoarthritis Pain Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Mexico Drugs for Osteoarthritis Pain Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Mexico Drugs for Osteoarthritis Pain Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Mexico Drugs for Osteoarthritis Pain Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Germany Drugs for Osteoarthritis Pain Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Germany Drugs for Osteoarthritis Pain Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Germany Drugs for Osteoarthritis Pain Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. France Drugs for Osteoarthritis Pain Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. France Drugs for Osteoarthritis Pain Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. France Drugs for Osteoarthritis Pain Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. U.K. Drugs for Osteoarthritis Pain Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. U.K. Drugs for Osteoarthritis Pain Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. U.K. Drugs for Osteoarthritis Pain Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Italy Drugs for Osteoarthritis Pain Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Italy Drugs for Osteoarthritis Pain Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Italy Drugs for Osteoarthritis Pain Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Spain Drugs for Osteoarthritis Pain Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Spain Drugs for Osteoarthritis Pain Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Spain Drugs for Osteoarthritis Pain Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Russia Drugs for Osteoarthritis Pain Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Russia Drugs for Osteoarthritis Pain Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Russia Drugs for Osteoarthritis Pain Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Netherlands Drugs for Osteoarthritis Pain Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Netherlands Drugs for Osteoarthritis Pain Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Netherlands Drugs for Osteoarthritis Pain Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Nordic Countries Drugs for Osteoarthritis Pain Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Nordic Countries Drugs for Osteoarthritis Pain Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Nordic Countries Drugs for Osteoarthritis Pain Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. China Drugs for Osteoarthritis Pain Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. China Drugs for Osteoarthritis Pain Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. China Drugs for Osteoarthritis Pain Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Japan Drugs for Osteoarthritis Pain Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Japan Drugs for Osteoarthritis Pain Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Japan Drugs for Osteoarthritis Pain Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. South Korea Drugs for Osteoarthritis Pain Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. South Korea Drugs for Osteoarthritis Pain Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. South Korea Drugs for Osteoarthritis Pain Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. India Drugs for Osteoarthritis Pain Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. India Drugs for Osteoarthritis Pain Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. India Drugs for Osteoarthritis Pain Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Australia Drugs for Osteoarthritis Pain Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Australia Drugs for Osteoarthritis Pain Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Australia Drugs for Osteoarthritis Pain Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Southeast Asia Drugs for Osteoarthritis Pain Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Southeast Asia Drugs for Osteoarthritis Pain Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Southeast Asia Drugs for Osteoarthritis Pain Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Brazil Drugs for Osteoarthritis Pain Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Brazil Drugs for Osteoarthritis Pain Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Brazil Drugs for Osteoarthritis Pain Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Argentina Drugs for Osteoarthritis Pain Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Argentina Drugs for Osteoarthritis Pain Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Argentina Drugs for Osteoarthritis Pain Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Chile Drugs for Osteoarthritis Pain Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Chile Drugs for Osteoarthritis Pain Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Chile Drugs for Osteoarthritis Pain Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Colombia Drugs for Osteoarthritis Pain Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Colombia Drugs for Osteoarthritis Pain Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Colombia Drugs for Osteoarthritis Pain Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Peru Drugs for Osteoarthritis Pain Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Peru Drugs for Osteoarthritis Pain Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Peru Drugs for Osteoarthritis Pain Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Saudi Arabia Drugs for Osteoarthritis Pain Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Saudi Arabia Drugs for Osteoarthritis Pain Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Drugs for Osteoarthritis Pain Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Israel Drugs for Osteoarthritis Pain Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Israel Drugs for Osteoarthritis Pain Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Israel Drugs for Osteoarthritis Pain Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. UAE Drugs for Osteoarthritis Pain Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. UAE Drugs for Osteoarthritis Pain Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. UAE Drugs for Osteoarthritis Pain Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Turkey Drugs for Osteoarthritis Pain Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Turkey Drugs for Osteoarthritis Pain Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Turkey Drugs for Osteoarthritis Pain Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Iran Drugs for Osteoarthritis Pain Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Iran Drugs for Osteoarthritis Pain Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Iran Drugs for Osteoarthritis Pain Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Egypt Drugs for Osteoarthritis Pain Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Egypt Drugs for Osteoarthritis Pain Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Egypt Drugs for Osteoarthritis Pain Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Years Considered Figure 115. Research Process Figure 116. Key Executives Interviewed

Scope & coverage.

Types
  • Oral
  • Injection
  • External
Applications
  • Medical Care
  • Personal Care
Companies covered
  • Pfizer
  • Johnson & Johnson
  • GlaxoSmithKline
  • Bayer
  • Eli Lilly
  • Novartis
  • Sanofi
  • Horizon Pharma
  • Abbott
  • Mylan
  • Daiichi Sankyo
  • TEVA
  • Almatica Pharma
  • Astellas Pharma
  • Tide Pharmaceutical
  • Iroko Pharmaceuticals
  • Hengrui Pharmaceutical
  • Abiogen Pharma

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Drugs for Osteoarthritis Pain Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Drugs for Osteoarthritis Pain Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Drugs for Osteoarthritis Pain Market Dynamics
  1. 2.1 Drugs for Osteoarthritis Pain Industry Trends
  2. 2.2 Drugs for Osteoarthritis Pain Industry Drivers
  3. 2.3 Drugs for Osteoarthritis Pain Industry Opportunities and Challenges
  4. 2.4 Drugs for Osteoarthritis Pain Industry Restraints
3 Drugs for Osteoarthritis Pain Market by Company
  1. 3.1 Global Drugs for Osteoarthritis Pain Company Revenue Ranking in 2025
  2. 3.2 Global Drugs for Osteoarthritis Pain Revenue by Company (2021-2026)
  3. 3.3 Global Drugs for Osteoarthritis Pain Company Ranking (2024-2026)
  4. 3.4 Global Drugs for Osteoarthritis Pain Company Manufacturing Base and Headquarters
  5. 3.5 Global Drugs for Osteoarthritis Pain Company Product Type and Application
  6. 3.6 Global Drugs for Osteoarthritis Pain Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Drugs for Osteoarthritis Pain Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Drugs for Osteoarthritis Pain Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Drugs for Osteoarthritis Pain Market by Type
  1. 4.1 Drugs for Osteoarthritis Pain Type Introduction
  2. 4.1.1 Oral
  3. 4.1.2 Injection
  4. 4.1.3 External
  5. 4.2 Global Drugs for Osteoarthritis Pain Sales Value by Type
  6. 4.2.1 Global Drugs for Osteoarthritis Pain Sales Value by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Drugs for Osteoarthritis Pain Sales Value by Type (2021-2032)
  8. 4.2.3 Global Drugs for Osteoarthritis Pain Sales Value Share by Type (2021-2032)
5 Drugs for Osteoarthritis Pain Market by Application
  1. 5.1 Drugs for Osteoarthritis Pain Application Introduction
  2. 5.1.1 Medical Care
  3. 5.1.2 Personal Care
  4. 5.2 Global Drugs for Osteoarthritis Pain Sales Value by Application
  5. 5.2.1 Global Drugs for Osteoarthritis Pain Sales Value by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Drugs for Osteoarthritis Pain Sales Value by Application (2021-2032)
  7. 5.2.3 Global Drugs for Osteoarthritis Pain Sales Value Share by Application (2021-2032)
6 Drugs for Osteoarthritis Pain Regional Value Analysis
  1. 6.1 Global Drugs for Osteoarthritis Pain Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Drugs for Osteoarthritis Pain Sales Value by Region (2021-2032)
  3. 6.2.1 Global Drugs for Osteoarthritis Pain Sales Value by Region: 2021-2026
  4. 6.2.2 Global Drugs for Osteoarthritis Pain Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Drugs for Osteoarthritis Pain Sales Value (2021-2032)
  7. 6.3.2 North America Drugs for Osteoarthritis Pain Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Drugs for Osteoarthritis Pain Sales Value (2021-2032)
  10. 6.4.2 Europe Drugs for Osteoarthritis Pain Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Drugs for Osteoarthritis Pain Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Drugs for Osteoarthritis Pain Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Drugs for Osteoarthritis Pain Sales Value (2021-2032)
  16. 6.6.2 South America Drugs for Osteoarthritis Pain Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Drugs for Osteoarthritis Pain Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Drugs for Osteoarthritis Pain Sales Value Share by Country, 2025 VS 2032
7 Drugs for Osteoarthritis Pain Country-level Value Analysis
  1. 7.1 Global Drugs for Osteoarthritis Pain Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Drugs for Osteoarthritis Pain Sales Value by Country (2021-2032)
  3. 7.2.1 Global Drugs for Osteoarthritis Pain Sales Value by Country (2021-2026)
  4. 7.2.2 Global Drugs for Osteoarthritis Pain Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Drugs for Osteoarthritis Pain Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Drugs for Osteoarthritis Pain Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Drugs for Osteoarthritis Pain Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Drugs for Osteoarthritis Pain Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Drugs for Osteoarthritis Pain Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Drugs for Osteoarthritis Pain Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Drugs for Osteoarthritis Pain Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Drugs for Osteoarthritis Pain Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Drugs for Osteoarthritis Pain Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Drugs for Osteoarthritis Pain Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Drugs for Osteoarthritis Pain Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Drugs for Osteoarthritis Pain Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Drugs for Osteoarthritis Pain Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Drugs for Osteoarthritis Pain Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Drugs for Osteoarthritis Pain Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Drugs for Osteoarthritis Pain Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Drugs for Osteoarthritis Pain Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Drugs for Osteoarthritis Pain Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Drugs for Osteoarthritis Pain Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Drugs for Osteoarthritis Pain Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Drugs for Osteoarthritis Pain Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Drugs for Osteoarthritis Pain Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Drugs for Osteoarthritis Pain Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Drugs for Osteoarthritis Pain Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Drugs for Osteoarthritis Pain Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Drugs for Osteoarthritis Pain Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Drugs for Osteoarthritis Pain Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Drugs for Osteoarthritis Pain Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Drugs for Osteoarthritis Pain Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Drugs for Osteoarthritis Pain Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Drugs for Osteoarthritis Pain Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Drugs for Osteoarthritis Pain Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Drugs for Osteoarthritis Pain Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Drugs for Osteoarthritis Pain Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Drugs for Osteoarthritis Pain Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Drugs for Osteoarthritis Pain Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Drugs for Osteoarthritis Pain Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Drugs for Osteoarthritis Pain Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Drugs for Osteoarthritis Pain Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Drugs for Osteoarthritis Pain Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Drugs for Osteoarthritis Pain Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Drugs for Osteoarthritis Pain Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Drugs for Osteoarthritis Pain Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Drugs for Osteoarthritis Pain Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Drugs for Osteoarthritis Pain Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Drugs for Osteoarthritis Pain Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Drugs for Osteoarthritis Pain Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Drugs for Osteoarthritis Pain Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Drugs for Osteoarthritis Pain Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Drugs for Osteoarthritis Pain Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Drugs for Osteoarthritis Pain Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Drugs for Osteoarthritis Pain Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Drugs for Osteoarthritis Pain Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Drugs for Osteoarthritis Pain Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Drugs for Osteoarthritis Pain Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Drugs for Osteoarthritis Pain Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Drugs for Osteoarthritis Pain Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Drugs for Osteoarthritis Pain Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Drugs for Osteoarthritis Pain Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Drugs for Osteoarthritis Pain Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Drugs for Osteoarthritis Pain Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Drugs for Osteoarthritis Pain Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Drugs for Osteoarthritis Pain Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Drugs for Osteoarthritis Pain Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Drugs for Osteoarthritis Pain Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Drugs for Osteoarthritis Pain Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Drugs for Osteoarthritis Pain Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Drugs for Osteoarthritis Pain Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Drugs for Osteoarthritis Pain Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Drugs for Osteoarthritis Pain Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Drugs for Osteoarthritis Pain Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Drugs for Osteoarthritis Pain Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Drugs for Osteoarthritis Pain Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Drugs for Osteoarthritis Pain Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Drugs for Osteoarthritis Pain Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Drugs for Osteoarthritis Pain Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Drugs for Osteoarthritis Pain Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Drugs for Osteoarthritis Pain Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Drugs for Osteoarthritis Pain Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Drugs for Osteoarthritis Pain Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Drugs for Osteoarthritis Pain Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Drugs for Osteoarthritis Pain Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Drugs for Osteoarthritis Pain Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Drugs for Osteoarthritis Pain Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Pfizer
  2. 8.1.1 Pfizer Company Information
  3. 8.1.2 Pfizer Business Overview
  4. 8.1.3 Pfizer Drugs for Osteoarthritis Pain Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Pfizer Drugs for Osteoarthritis Pain Product Portfolio
  6. 8.1.5 Pfizer Recent Developments
  7. 8.2 Johnson & Johnson
  8. 8.2.1 Johnson & Johnson Company Information
  9. 8.2.2 Johnson & Johnson Business Overview
  10. 8.2.3 Johnson & Johnson Drugs for Osteoarthritis Pain Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Johnson & Johnson Drugs for Osteoarthritis Pain Product Portfolio
  12. 8.2.5 Johnson & Johnson Recent Developments
  13. 8.3 GlaxoSmithKline
  14. 8.3.1 GlaxoSmithKline Company Information
  15. 8.3.2 GlaxoSmithKline Business Overview
  16. 8.3.3 GlaxoSmithKline Drugs for Osteoarthritis Pain Revenue and Gross Margin (2021-2026)
  17. 8.3.4 GlaxoSmithKline Drugs for Osteoarthritis Pain Product Portfolio
  18. 8.3.5 GlaxoSmithKline Recent Developments
  19. 8.4 Bayer
  20. 8.4.1 Bayer Company Information
  21. 8.4.2 Bayer Business Overview
  22. 8.4.3 Bayer Drugs for Osteoarthritis Pain Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Bayer Drugs for Osteoarthritis Pain Product Portfolio
  24. 8.4.5 Bayer Recent Developments
  25. 8.5 Eli Lilly
  26. 8.5.1 Eli Lilly Company Information
  27. 8.5.2 Eli Lilly Business Overview
  28. 8.5.3 Eli Lilly Drugs for Osteoarthritis Pain Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Eli Lilly Drugs for Osteoarthritis Pain Product Portfolio
  30. 8.5.5 Eli Lilly Recent Developments
  31. 8.6 Novartis
  32. 8.6.1 Novartis Company Information
  33. 8.6.2 Novartis Business Overview
  34. 8.6.3 Novartis Drugs for Osteoarthritis Pain Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Novartis Drugs for Osteoarthritis Pain Product Portfolio
  36. 8.6.5 Novartis Recent Developments
  37. 8.7 Sanofi
  38. 8.7.1 Sanofi Company Information
  39. 8.7.2 Sanofi Business Overview
  40. 8.7.3 Sanofi Drugs for Osteoarthritis Pain Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Sanofi Drugs for Osteoarthritis Pain Product Portfolio
  42. 8.7.5 Sanofi Recent Developments
  43. 8.8 Horizon Pharma
  44. 8.8.1 Horizon Pharma Company Information
  45. 8.8.2 Horizon Pharma Business Overview
  46. 8.8.3 Horizon Pharma Drugs for Osteoarthritis Pain Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Horizon Pharma Drugs for Osteoarthritis Pain Product Portfolio
  48. 8.8.5 Horizon Pharma Recent Developments
  49. 8.9 Abbott
  50. 8.9.1 Abbott Company Information
  51. 8.9.2 Abbott Business Overview
  52. 8.9.3 Abbott Drugs for Osteoarthritis Pain Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Abbott Drugs for Osteoarthritis Pain Product Portfolio
  54. 8.9.5 Abbott Recent Developments
  55. 8.10 Mylan
  56. 8.10.1 Mylan Company Information
  57. 8.10.2 Mylan Business Overview
  58. 8.10.3 Mylan Drugs for Osteoarthritis Pain Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Mylan Drugs for Osteoarthritis Pain Product Portfolio
  60. 8.10.5 Mylan Recent Developments
  61. 8.11 Daiichi Sankyo
  62. 8.11.1 Daiichi Sankyo Company Information
  63. 8.11.2 Daiichi Sankyo Business Overview
  64. 8.11.3 Daiichi Sankyo Drugs for Osteoarthritis Pain Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Daiichi Sankyo Drugs for Osteoarthritis Pain Product Portfolio
  66. 8.11.5 Daiichi Sankyo Recent Developments
  67. 8.12 TEVA
  68. 8.12.1 TEVA Company Information
  69. 8.12.2 TEVA Business Overview
  70. 8.12.3 TEVA Drugs for Osteoarthritis Pain Revenue and Gross Margin (2021-2026)
  71. 8.12.4 TEVA Drugs for Osteoarthritis Pain Product Portfolio
  72. 8.12.5 TEVA Recent Developments
  73. 8.13 Almatica Pharma
  74. 8.13.1 Almatica Pharma Company Information
  75. 8.13.2 Almatica Pharma Business Overview
  76. 8.13.3 Almatica Pharma Drugs for Osteoarthritis Pain Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Almatica Pharma Drugs for Osteoarthritis Pain Product Portfolio
  78. 8.13.5 Almatica Pharma Recent Developments
  79. 8.14 Astellas Pharma
  80. 8.14.1 Astellas Pharma Company Information
  81. 8.14.2 Astellas Pharma Business Overview
  82. 8.14.3 Astellas Pharma Drugs for Osteoarthritis Pain Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Astellas Pharma Drugs for Osteoarthritis Pain Product Portfolio
  84. 8.14.5 Astellas Pharma Recent Developments
  85. 8.15 Tide Pharmaceutical
  86. 8.15.1 Tide Pharmaceutical Company Information
  87. 8.15.2 Tide Pharmaceutical Business Overview
  88. 8.15.3 Tide Pharmaceutical Drugs for Osteoarthritis Pain Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Tide Pharmaceutical Drugs for Osteoarthritis Pain Product Portfolio
  90. 8.15.5 Tide Pharmaceutical Recent Developments
  91. 8.16 Iroko Pharmaceuticals
  92. 8.16.1 Iroko Pharmaceuticals Company Information
  93. 8.16.2 Iroko Pharmaceuticals Business Overview
  94. 8.16.3 Iroko Pharmaceuticals Drugs for Osteoarthritis Pain Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Iroko Pharmaceuticals Drugs for Osteoarthritis Pain Product Portfolio
  96. 8.16.5 Iroko Pharmaceuticals Recent Developments
  97. 8.17 Hengrui Pharmaceutical
  98. 8.17.1 Hengrui Pharmaceutical Company Information
  99. 8.17.2 Hengrui Pharmaceutical Business Overview
  100. 8.17.3 Hengrui Pharmaceutical Drugs for Osteoarthritis Pain Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Hengrui Pharmaceutical Drugs for Osteoarthritis Pain Product Portfolio
  102. 8.17.5 Hengrui Pharmaceutical Recent Developments
  103. 8.18 Abiogen Pharma
  104. 8.18.1 Abiogen Pharma Company Information
  105. 8.18.2 Abiogen Pharma Business Overview
  106. 8.18.3 Abiogen Pharma Drugs for Osteoarthritis Pain Revenue and Gross Margin (2021-2026)
  107. 8.18.4 Abiogen Pharma Drugs for Osteoarthritis Pain Product Portfolio
  108. 8.18.5 Abiogen Pharma Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst